Enhanced Genomics leverages a proprietary 3D multi-omics platform and a cell-type specific atlas to map whole-genome interactions and translate vast disease-associated datasets into high-confidence, genetically validated drug targets. By focusing on causal biology, the company aims to raise the probability of success in pharmaceutical development while cutting time and cost. Its technology is positioned to address complex genetic diseases with significant unmet needs, including autoimmune disorders such as inflammatory bowel disease. The firm plans to build an internal therapeutics pipeline and also pursue strategic partnerships with pharmaceutical and biotech companies to scale output and generate asset-based opportunities. Leadership claims the platform delivers targets for high-value indications in a fraction of the traditional timeline. To date, the company has secured a total of USD 19 million in Series A funding to fuel these initiatives. No revenue or user metrics were disclosed in the article.

Total raised

$30M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2025